{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:51:50Z","timestamp":1780512710311,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.leukres.2025.107920","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T06:42:31Z","timestamp":1753166551000},"page":"107920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Outcomes with intensive chemotherapy, compared to hypomethylating agent + venetoclax, in patients with intermediate and adverse risk acute myeloid leukemia"],"prefix":"10.1016","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2300-4499","authenticated-orcid":false,"given":"Todd William","family":"Mudd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6129-3470","authenticated-orcid":false,"given":"Kendall","family":"Diebold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Parks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maris","family":"Hardee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Jarodiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7906-8782","authenticated-orcid":false,"given":"Manuel","family":"Espinoza-Gutarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimo","family":"Bachiashvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravanti","family":"Rangaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0189-8233","authenticated-orcid":false,"given":"Razan","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5740-2316","authenticated-orcid":false,"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2411-4742","authenticated-orcid":false,"given":"Omer","family":"Jamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2025.107920_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720913010","article-title":"Low-intensity regimens versus standard-intensity induction strategies in acute myeloid leukemia","volume":"11","author":"Vey","year":"2020","journal-title":"Ther. Adv. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2025.107920_bib2","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2025.107920_bib3","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2025.107920_bib4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41375-023-02073-x","article-title":"A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML","volume":"38","author":"Garcia-Manero","year":"2024","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2025.107920_bib5","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.leukres.2025.107920_bib6","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.leukres.2025.107920_bib7","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","article-title":"A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients","volume":"125","author":"Burnett","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2025.107920_bib8","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1182\/bloodadvances.2020001728","article-title":"Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States","volume":"4","author":"Zeidan","year":"2020","journal-title":"Blood Adv."},{"issue":"18","key":"10.1016\/j.leukres.2025.107920_bib9","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2025.107920_bib10","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1200\/JCO.2014.55.1564","article-title":"Acute myeloid leukemia and myelodysplastic syndromes in older adults","volume":"32","author":"Klepin","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2025.107920_bib11","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/cncr.22496","article-title":"A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment","volume":"109","author":"Burnett","year":"2007","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.leukres.2025.107920_bib12","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/cncr.29367","article-title":"Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia","volume":"121","author":"Kadia","year":"2015","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.leukres.2025.107920_bib13","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ajh.25198","article-title":"Sorafenib combined with 5-azacytidine in older patients with untreated FLT3-ITD mutated acute myeloid leukemia","volume":"93","author":"Ohanian","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2025.107920_bib14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.leukres.2025.107920_bib15","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2025.107920_bib16","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1007\/s00277-021-04565-1","article-title":"Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials","volume":"100","author":"Heinicke","year":"2021","journal-title":"Ann. Hematol."},{"issue":"24","key":"10.1016\/j.leukres.2025.107920_bib17","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.leukres.2025.107920_bib18","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/ajh.26991","article-title":"Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia","volume":"98","author":"Matthews","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2025.107920_bib19","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2024-202801","article-title":"Venetoclax and decitabine compared with standard intensive chemotherapy as induction therapy in newly diagnosed acute myeloid leukemia: updated results of a multicenter, randomized, phase 2b trial","volume":"144","author":"Lu","year":"2024","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.leukres.2025.107920_bib20","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1182\/bloodadvances.2022009632","article-title":"Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation","volume":"7","author":"Short","year":"2023","journal-title":"Blood Adv."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625002802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625002802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T13:56:33Z","timestamp":1756821393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625002802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":20,"alternative-id":["S0145212625002802"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107920","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes with intensive chemotherapy, compared to hypomethylating agent + venetoclax, in patients with intermediate and adverse risk acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107920","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107920"}}